Search

Your search keyword '"Szado, Tania"' showing total 40 results

Search Constraints

Start Over You searched for: Author "Szado, Tania" Remove constraint Author: "Szado, Tania"
40 results on '"Szado, Tania"'

Search Results

2. Clinical Value of Timely Targeted Therapy for Patients With Advanced Non–Small Cell Lung Cancer With Actionable Driver Oncogenes

3. MyPathway Human Epidermal Growth Factor Receptor 2 Basket Study: Pertuzumab + Trastuzumab Treatment of a Tissue-Agnostic Cohort of Patients With Human Epidermal Growth Factor Receptor 2–Altered Advanced Solid Tumors

4. Improving biomarker testing in advanced non-small-cell lung cancer and metastatic colorectal cancer: experience from a large community oncology network in the USA

5. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial

6. Abstract 2267: Biomarker testing and treatment (tx) patterns in a large community oncology network

7. Abstract CT032: Activity and safety of alectinib for ALK-altered solid tumors from MyPathway

8. Abstract CT128: A study evaluating targeted therapies in participants who have advanced solid tumors with genomic alterations or protein expression patterns predictive of response (MyTACTIC)

9. Evolution of biomarker testing in advanced non-small cell lung cancer (aNSCLC) and metastatic breast cancer (mBC) in U.S. community practices.

11. Biomarker testing patterns and actionability in advanced non-small cell lung cancer (aNSCLC) at OneOncology (OneOnc).

12. NGS testing patterns in advanced non-small cell lung cancer (aNSCLC) and metastatic breast cancer (mBC): OneOncology (OO) sites compared to Flatiron Health Nationwide (NAT).

13. A study evaluating targeted therapies in participants who have advanced solid tumors with genomic alterations or protein expression patterns predictive of response (MyTACTIC).

14. Sequential opening of I[P.sub.3]-sensitive [Ca.sup.2+] channels and SOC during [alpha]-adrenergic activation of rabbit vena cava

18. Additional file 2: of Biomarker analysis of the NeoSphere study: pertuzumab, trastuzumab, and docetaxel versus trastuzumab plus docetaxel, pertuzumab plus trastuzumab, or pertuzumab plus docetaxel for the neoadjuvant treatment of HER2-positive breast cancer

19. Additional file 1: Table S1. of Biomarker analysis of the NeoSphere study: pertuzumab, trastuzumab, and docetaxel versus trastuzumab plus docetaxel, pertuzumab plus trastuzumab, or pertuzumab plus docetaxel for the neoadjuvant treatment of HER2-positive breast cancer

20. Role of sarcoplasmic reticulum in regulation of tonic contraction of rabbit basilar artery

21. Biomarker analysis of the NeoSphere study: pertuzumab, trastuzumab, and docetaxel versus trastuzumab plus docetaxel, pertuzumab plus trastuzumab, or pertuzumab plus docetaxel for the neoadjuvant treatment of HER2-positive breast cancer

24. Role of sarcoplasmic reticulum and mitochondria in Ca2+ signaling in vascular smooth muscle

28. Pertuzumab Monotherapy After Trastuzumab-Based Treatment and Subsequent Reintroduction of Trastuzumab: Activity and Tolerability in Patients With Advanced Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer

29. Phosphorylation of inositol 1,4,5-trisphosphate receptors by protein kinase B/Akt inhibits Ca 2+ release and apoptosis

36. Phosphorylation of inositol 1,4,5-trisphosphate receptors by protein kinase B/Akt inhibits Ca2+ release and apoptosis.

37. Endothelin-1-Mediated Wave-Like [Ca]i Oscillations in Intact Rabbit Inferior Vena Cava.

39. Sequential opening of IP3-sensitive Ca2+ channels and SOC during α-adrenergic activation of rabbit vena cava.

40. Agonist-induced mitochondrial Ca2+ transients in smooth muscle.

Catalog

Books, media, physical & digital resources